Lista de obras - Frédéric R Santer - Dominio Público Uruguay

Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

artículo científico publicado en 2011

Androgen receptor signaling in prostate cancer.

artículo científico

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer

artículo científico publicado en 2016

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways

artículo científico publicado en 2009

Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation.

artículo científico publicado en 2007

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 ⬇️

artículo científico publicado el 23 de agosto de 2013

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines

artículo científico publicado en 2011

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

artículo científico publicado en 2017

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

artículo científico publicado en 2015

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer ⬇️

artículo científico publicado el 30 de abril de 2013

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

artículo científico publicado en 2018

Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.

artículo científico publicado en 2006

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

artículo científico publicado en 2018

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

artículo científico publicado en 2010

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways ⬇️

artículo científico publicado el 3 de mayo de 2012

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

artículo científico publicado en 2009

The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models

artículo científico publicado en 2018

Therapy escape mechanisms in the malignant prostate

artículo científico publicado en 2015

Transcriptional coactivators p300 and CBP stimulate estrogen receptor‐beta signaling and regulate cellular events in prostate cancer ⬇️

artículo científico publicado el 21 de septiembre de 2010

Lista de obras de Frédéric R Santer

Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

Androgen receptor signaling in prostate cancer.

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways

Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation.

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 ⬇️

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer ⬇️

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways ⬇️

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models

Therapy escape mechanisms in the malignant prostate

Transcriptional coactivators p300 and CBP stimulate estrogen receptor‐beta signaling and regulate cellular events in prostate cancer ⬇️